USFDA classifies Jubilant Pharmova's Spokane CMO Facility as VAI

The VAI classification signifies that objectionable conditions or practices were observed during the inspection

Jubilant Pharmova Limited announced that the USFDA has concluded its review of the Establishment Inspection Report (EIR) for the inspection conducted at Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA, from June 8, 2026, to June 17, 2026, and has classified the facility as "Voluntary Action Indicated (VAI)".

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding, which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of the company.

The VAI classification signifies that while objectionable conditions or practices were observed during the inspection, the agency does not intend to take or recommend any administrative or regulatory action.